Shares of Abiomed (NASDAQ:ABMD) were unchanged after the company reported Q3 results.
Quarterly Results
Earnings per share rose 20.54% year over year to $1.35, which beat the estimate of $1.13.
Revenue of $231,663,000 higher by 4.55% from the same period last year, which beat the estimate of $225,590,000.
Looking Ahead
Q4 revenue expected to be between $225,000,000 and $235,000,000.
Details Of The Call
Date: Jan 28, 2021
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/y64ndzmr
Technicals
Company's 52-week high was at $353.49
52-week low: $119.01
Price action over last quarter: Up 30.46%
Company Profile
Abiomed Inc provides temporary mechanical circulatory support devices that are primarily used by interventional cardiologists and heart surgeons. The firm's products are used for patients in need of hemodynamic support before, during, or after angioplasty and heart surgery procedures. Abiomed receives the majority of revenue from its Impella product portfolio, which includes percutaneous micro heart pumps with integration motors and sensors and percutaneous catheter-based axial flow pumps. Abiomed generates the majority of its revenue in the United States.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
